These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23606319)

  • 21. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
    Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
    Höti N; Chowdhury W; Hsieh JT; Sachs MD; Lupold SE; Rodriguez R
    Mol Ther; 2006 Dec; 14(6):768-78. PubMed ID: 16990052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies.
    van Putten EHP; Kleijn A; van Beusechem VW; Noske D; Lamers CHJ; de Goede AL; Idema S; Hoefnagel D; Kloezeman JJ; Fueyo J; Lang FF; Teunissen CE; Vernhout RM; Bakker C; Gerritsen W; Curiel DT; Vulto A; Lamfers MLM; Dirven CMF
    Clin Cancer Res; 2022 Apr; 28(8):1572-1585. PubMed ID: 35176144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.
    Shin DH; Jiang H; Gillard AG; Kim D; Fan X; Singh SK; Nguyen TT; Sohoni SS; Lopez-Rivas AR; Parthasarathy A; Ene CI; Gumin J; Lang FF; Alonso MM; Gomez-Manzano C; Fueyo J
    Mol Ther; 2024 Mar; 32(3):722-733. PubMed ID: 38311852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy.
    Ulasov IV; Shah N; Kaverina NV; Lee H; Lin B; Lieber A; Kadagidze ZG; Yoon JG; Schroeder B; Hothi P; Ghosh D; Baryshnikov AY; Cobbs CS
    Oncotarget; 2015 Feb; 6(6):3977-87. PubMed ID: 25738357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.
    Lang FF; Conrad C; Gomez-Manzano C; Yung WKA; Sawaya R; Weinberg JS; Prabhu SS; Rao G; Fuller GN; Aldape KD; Gumin J; Vence LM; Wistuba I; Rodriguez-Canales J; Villalobos PA; Dirven CMF; Tejada S; Valle RD; Alonso MM; Ewald B; Peterkin JJ; Tufaro F; Fueyo J
    J Clin Oncol; 2018 May; 36(14):1419-1427. PubMed ID: 29432077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs.
    Ji-qun C; Ishihara K; Nagayama T; Serikawa T; Sasa M
    Epilepsia; 2005 Sep; 46(9):1362-70. PubMed ID: 16146430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma.
    Bieler A; Mantwill K; Holzmüller R; Jürchott K; Kaszubiak A; Stärk S; Glockzin G; Lage H; Grosu AL; Gansbacher B; Holm PS
    Radiother Oncol; 2008 Mar; 86(3):419-27. PubMed ID: 17967494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer.
    Page JG; Tian B; Schweikart K; Tomaszewski J; Harris R; Broadt T; Polley-Nelson J; Noker PE; Wang M; Makhija S; Aurigemma R; Curiel DT; Alvarez RD
    Am J Obstet Gynecol; 2007 Apr; 196(4):389.e1-9; discussion 389.e9-10. PubMed ID: 17403430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
    Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
    J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death.
    Alonso MM; Jiang H; Yokoyama T; Xu J; Bekele NB; Lang FF; Kondo S; Gomez-Manzano C; Fueyo J
    Mol Ther; 2008 Mar; 16(3):487-93. PubMed ID: 18253154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats.
    van Vliet EA; Edelbroek PM; Gorter JA
    Epilepsia; 2010 Mar; 51(3):362-70. PubMed ID: 19674045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
    Mink S; Muroi C; Seule M; Bjeljac M; Keller E
    Clin Neurol Neurosurg; 2011 Oct; 113(8):644-8. PubMed ID: 21703756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of levetiracetam and valproate on reproductive endocrine function studied in human ovarian follicular cells.
    Taubøll E; Gregoraszczuk EL; Wojtowicz AK; Milewicz T
    Epilepsia; 2009 Aug; 50(8):1868-74. PubMed ID: 19490055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy.
    González-Morales A; Zabaleta A; García-Moure M; Alonso MM; Fernández-Irigoyen J; Santamaría E
    J Proteomics; 2019 Mar; 194():168-178. PubMed ID: 30503830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
    Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
    Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity.
    Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
    Oncoimmunology; 2014 Oct; 3(9):e955697. PubMed ID: 25941622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Oncolytic properties of some orthopoxviruses, adenoviruses and parvoviruses in human glioma cells].
    Razumov IA; Sviatchenko VA; Protopopova EV; Kochneva GV; Kiselev NN; Gubanova NV; Shilov AG; Mordvinov VA; Netesov SV; Chumakov PM; Loktev VB
    Vestn Ross Akad Med Nauk; 2013; (12):4-8. PubMed ID: 24741936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.
    Lamfers ML; Idema S; Bosscher L; Heukelom S; Moeniralm S; van der Meulen-Muileman IH; Overmeer RM; van der Valk P; van Beusechem VW; Gerritsen WR; Vandertop WP; Dirven CM
    Clin Cancer Res; 2007 Dec; 13(24):7451-8. PubMed ID: 18094429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.
    Guse K; Diaconu I; Rajecki M; Sloniecka M; Hakkarainen T; Ristimäki A; Kanerva A; Pesonen S; Hemminki A
    Gene Ther; 2009 Aug; 16(8):1009-20. PubMed ID: 19440223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.